Skip to main content

Bristol-Myers defends Celgene bet as investor criticism grows

By Reuters  
   March 06, 2019

Bristol-Myers Squibb defended its planned $74 billion takeover of Celgene Corp, saying it had carried out a “robust” assessment of the merger after two major investors opposed what could be the largest pharmaceutical deal ever.

Full story


Get the latest on healthcare leadership in your inbox.